FINWIRES · TerminalLIVE
FINWIRES

Inspire Medical Systems Faces Limited Visibility, RBC Says

By

Inspire Medical Systems (INSP) has limited visibility on near- and medium-term trends after the firm lowered its 2026 revenue guidance due to impact of Inspire V coding headwinds, RBC Capital Markets said in a Monday note.

The report said the guidance cut is reflecting accelerated coding and reimbursement challenges to Inspire V, while additional WISeR/GLP-1 headwinds emerge.

The headwinds align with intra-quarter RBC Doctor Day checks that highlighted that several factors will likely continue to drive Inspire volumes lower throughout 2026, it said.

The report also said the medical technology company, which focuses on obstructive sleep apnea, doesn't expect a new CPT code for Inspire V until Jan. 1, 2028.

"We remain on the sidelines due to lack of visibility," the note said. RBC kept its Sector Perform rating while lowering its price target to $45 from $56.

Price: $45.71, Change: $-9.13, Percent Change: -16.65%

Related Articles

Wire

IAC Q1 Loss Narrows, Revenue Falls; Shares Drop After Hours

IAC (IAC) reported a Q1 loss late Monday of $0.94 per diluted share, narrowing from the loss of $2.64 a year earlier.Analysts polled by FactSet expected a loss of $0.37.Revenue in the three months ended March 31 fell to $422.9 million from $481.7 million a year earlier.Analysts surveyed by FactSet expected $520.3 million.IAC shares fell 8.6% in after-hours trading.

$IAC
Wire

Vornado Realty Trust Q1 Non-GAAP FFO, Revenue Fall; Shares Drop After Hours

Vornado Realty Trust (VNO) reported Q1 non-GAAP funds from operations late Monday of $0.52 per diluted share, down from $0.63 a year earlier.Analysts polled by FactSet expected $0.51.Revenue in the three months ended March 31 fell to $459.1 million from $461.6 million a year earlier.Analysts surveyed by FactSet expected $431.7 million.Vornado shares fell 3% in after-hours trading.

$VNO
Wire

GeneDx Q1 Swings to Adjusted Loss, Revenue Rises; 2026 Revenue Guidance Lowered; Shares Fall

GeneDx (WGS) reported Monday Q1 adjusted loss of $0.28 per diluted share, swinging from an adjusted earnings of $0.31 a year earlier.Analysts polled by FactSet expected loss of $0.02.Revenue for the quarter ended March 31 was $102.3 million, up from $87.1 million a year earlier.Analysts surveyed by FactSet expected $112.5 million.For Q2, the company expects revenue of $110 million to $112 million. Analysts expect $130.3 million.The company now expects 2026 revenue of $475 million to $490 million, down from $540 million to $555 million expected earlier. Analysts expect $550.0 million.Shares of the company were down over 45% during after-hours activity.

$WGS